Introduction
Hereditary neurometabolic disorders are rare in the general population but relatively common in Jordan due to the high rate of consanguineous marriage. 1 Neurometabolic disorders are a major risk factor for global developmental delay (GDD) in Jordanian children, accounting for 13% of all GDD cases, 2 a Figure 10 times higher than reported in other countries. 3 Neurometabolic disorders are not a frequent cause of epilepsy, but epilepsy is a frequent comorbidity in many neurometabolic disorders. [4] [5] [6] However, a previous study from Jordan on the causes of neonatal seizures concluded that neurometabolic disorders account for 28.6% of all neonatal seizure cases 7 compared to 9% in previous studies on other populations. 8, 9 Most previous studies on epilepsies associated with neurometabolic disorders addressed seizure characteristics in specific neurometabolic disease entities, [10] [11] [12] while few studies have examined the incidence and clinical characteristics of epilepsy in neurometabolic disorders as a group. 13, 14 To our knowledge, no such study has been conducted in Jordan.
Objectives of the study
To examine the characteristics of epilepsy in children with neurometabolic disorders to reveal co morbidities and optimal treatment.
Patients and methods
biochemical analyses of respiratory chain enzymes. The diagnosis of mucopolysaccharidosis was based solely on a positive urine test for mucopolysaccharides as specific lysosomal enzyme essays were not available at the time of study. Diagnosis of pyridoxine dependency was based on the clinical picture, failure of seizures to respond to antiepileptic treatments, and normalization of the EEG with suppression of seizures in response to pyridoxine.
We defined complete control of seizures as the disappearance of all seizures for at least 3 months. Although this is not a widely accepted definition, we used it in this study as an indicator of epilepsy control. We defined partial control of seizures as a decrease in seizures frequency of at least 25% from baseline as reported by parents. We defined ''no response'' as a reduction in seizure frequency of less than 25% as reported by parents.
Results

Patients' characteristics
During the study period, 70 patients were diagnosed with a neurometabolic disorder (40 boys and 30 girls). The total duration of follow-up ranged from 3 months to 5.5 years. The neurometabolic disorders encountered included: mitochondrial disorders (18 patients) lysosomal disorders (22 patients), peroxysomal disorders (4 patients) amino acid disorders (10 patients), organic acid disorders (5 patients) Canavan disease (2 patients), vitamins and trace element disorders (8 patients), and urea cycle defect (one patient). The specific disorders in each group are presented in Table 1 .
Twenty-nine of these patients (41.4%) were also diagnosed with epilepsy. The frequency of concurrent epilepsy varied among the different disorders and ranged from 0% to 100%. The frequency of epilepsy among the different disorders included: 1/1 patient or 100% in the urea cycle defect, 5/8 patients or 62.5% in the vitamins and trace element group, 6/10 patients or 60% in the amino acid disorders, 1/2 patients or 50% in Canavan disease, 7/18 patients or 38.9% in the mitochondrial disorders, 8/22 patients or 36.4% in the lysosomal disorders, 1/5 patients or 20% in the organic acid disorders and 0/4 patients or 0% in the peroxysomal disorders (Table 1 ). In the lysosomal disorders, disorders of sphingolipid metabolism were most frequently associated with epilepsy (8/13 patients or 61.5%), notably neuronal ceroid lipofuscinosis (4/ 4patients or 100%) and metachromatic leukodystrophy (4/7 patients or 57.1%), while mucopolysacharidosis, Neimann pick disease type c and Gaucher disease were not associated with epilepsy (0%). In the amino acid disorders, nonketotic hyperglycinemia (1/1 patient or 100%) and homocystinurea (3/7 patients or 75%) were most frequently associated with epilepsy. In the vitamin related disorders all patients had associated epilepsy (100%) while none of the patients with Wilson disease had epilepsy (Table 1 ).
Epilepsy characteristics
The age at onset of epilepsy ranged from 3 days to 7 years. Onset of seizures occurred in the first year of life in 15/29 patients (51.7%), between 13 months and 4 years of age in 8/29 patients (27.6%), and after age 4 years in 6/29 patients (20.6%). Seizures were the first presenting symptom of the disease in 12 patients (41.4%); this included all patients with pyridoxine dependency, all patients with neuronal ceroid lipofuscinosis, one patient with non ketotic hyperglycinemia, one patient with biotinidase deficiency and two patients with mitochondrial disorders. All types of seizures were reported; however, generalized tonic-clonic and mixed types were the most common (16/29 patients, 55.2%) and each occurred with approximately equal frequency. Other types of seizures observed in neurometabolic disease patients included myoclonic in 6 patients (20.6%), tonic in 4 patients (13.8%), simple focal in one patient (3.4%), partial complex in one patient (3.4%), and infantile spasms in one patient (3.4%) ( Table 2) . Status epilepticus was reported in only 3/29 epilepsy patients (10.3%). Classification of seizures into epileptic syndromes was possible in only 6/29 patients (20.7%). All four patients with neuronal ceroid lipofuscinosis were classified into progressive myoclonic epilepsy, one patient with pyridoxine dependency and one patient with methylmalonic academia were classified into west syndrome, and one patient with non ketotic hyperglycinemia was classified into early myoclonic encephalopathy.
All 29 comorbid patients were taking either a single antiepileptic drug (16/29 patients, 55.2%) or multiple drugs (13/29 patients, 44.7%). The most common antiepileptic drugs used as monotherapy or in combination were the older generation anticonvulsants phenobarbital, clonazepam, valproic acid, and carbamazepine (22/29 patients, 75.8%). The newer antiepileptic drugs lamotragine, topiramate, and levetiracetam were prescribed to 7/29 patients (24.1%). In our clinic the old antiepileptic drugs are tried first; newer antiepileptic drugs are usually started as add on drugs only if older drugs were tried and failed to suppress seizures. The newer antiepileptic drugs are usually tapered and stopped if they did not control seizures after titration to maximal dose. None of our patients received non-pharmaceutical treatments such as surgery, ketogenic diet, or vagal nerve stimulation. Complete control of seizures was achieved in 19/29 patients (65.5%) and partial control in 7/29 patients (24.1%), while 3/29 patients (10.3%) exhibited poor or no response to both older and newer generation antiepileptic drugs. Epilepsy associated with vitamin related disorders was controlled in all cases except one patient who had recurrent status epilepticus evoked by fever and infections. Epilepsy was controlled in most patients with amino acid, organic acid, and urea cycle disorders. Similarly, seizures were controlled in most patients (70%) with mitochondrial disorders. In the lysosomal disorders, seizures were controlled in all the patients with metachromatic leukodystrophy. In contrast, seizures were not controlled in patients with neuronal ceroid lipofusinosis.
Electroencephalographic recordings were missing from the medical files of 10/29 patients (34.4%). The first EEG was normal in 7/19 epilepsy patients (36.8%). Epileptiform activity, including both focal and generalized spikes, polyspikes, suppression burst and slow waves, were observed in 12/19 patients (63.2%) on the initial EEG.
Brain MRI revealed a variety of abnormalities, including brain atrophy, white matter changes, and basal ganglia changes. The types of neurometabolic disorders presenting with epilepsy, the clinical characteristics, EEG findings, and brain MRI findings are shown in Table 2 4.3. Family history A history of consanguinity was present in 54/70 patients (77.1%). A family history of epilepsy was evident in 16/70 patients (22.8%), of which 13 (81.2%) were from the epileptic group.
Discussion
Epilepsy in patients with neurometabolic disorders may be classified according to clinical or etiopathogenetical criteria. 12 Distinguishing clinical characteristics include age at onset, seizure type, specific EEG patterns, and epilepsy syndromes. 12 Epilepsy in our study was a frequent comorbidity in many neurometabolic disorders, but the concurrence rate among individual neurometabolic disorders ranged from 0% to 100%. Nearly half of all patients with a neurometabolic disorder (41.4%) in our study had epilepsy, in accordance with the 43% reported by Turki et al. 14 In the mitochondrial disorders more than one third of our patients (38.9%) had epilepsy, ongoing with previous studies reporting epilepsy in 26%-60% of all mitochondrial disorders. [15] [16] [17] Previous studies revealed that epilepsy in mitochondrial disorders was more common in patients with early onset disease and with severe psychomotor retardation. 4 In the lysosomal storage disorders, epilepsy varied among the different types of diseases, being was most frequent in neuronal ceroid lipofuscinosis (100%) and metachromatic leukodystrophy (57.1%) and rare in Neimann pick disease (0%) Gaucher disease (0%) and mucopolysacharidosis (0%). Our results are in accordance with previous results in the literature which reported epilepsy as a major feature of neuronal ceroid lipofuscinosis 18 and metachromatic leukodystrophy. 19 In Gaucher disease, a study conducted by the International Collaborative Gaucher Group reported that 16% of patients with Gaucher's disease have epilepsy. 20 In NeimannPick disease, previous studies reported epilepsy as a late onset manifestation characterized most often by partial, generalized tonic-clonic, or atonic seizures. 21 None of our patients with mucopolysaccharidois had epilepsy and to our knowledge, no study in English have reported the risk of epilepsy in mucopolysaccharidosis as a collective group, so these cases suggest that comorbidity is rare. Furthermore non of our patients with peroxysomal disorders had epilepsy. In a large series of X-linked adrenoleukodystrophy patients, only 20 of 485 (4.1%) presented with seizures, including focal generalized seizures and status epilepticus, 22 while in Zellweger syndrome, epilepsy is typically characterized by focal clonic seizures originating in or around cortical malformations. 23 In amino acid disorders and urea cycle disorders, epilepsy in our study was a frequent association; (60%-100%) respectively, while it was uncommon in the organic academia occurring in only one fifth of the patients (20%). Previous studies in the literature reported epilepsy to be a frequent association during the early stages of amino acid, organic acids and urea cycle disorders, but rare when the underlying disease is under control and when there is no irreversible brain damage. 4 In the vitamins and trace elements group non of our patients with Wilson disease had epilepsy ongoing with previous studies in the literature reporting seizures to be unusual, occurring in only 4.2%-6.2% of patients 24, 25 ; with status epilepticus being exceptionally rare. 26 Regardless of the specific neurometabolic disorder, epilepsy in our patients most often presented at an early age, with onset more common before one year and uncommon after 4 years of age. The clinical characteristics of epilepsy associated with neurometabolic disorders are a reflection of the underlying metabolic abnormality, and apart from a few epileptic syndromes neither the EEG pattern nor the type of seizures is specific to the disorder. 27 In our study, all types of seizures were reported, though generalized tonic-clonic and mixed types were the most common, occurring in around half of the patients. Status epilepticus in our study was uncommon, occurring in only 10.3% of patients. Our results are ongoing with previous studies, as in most cases reported, epilepsy secondary to a neurometabolic disorder presents with polymorphic clinical and EEG features, although focal seizures have been reported to be more common than generalized seizures. 12 Furthermore, status epilepticus was reported from previous studies to occur in almost all inborn errors of metabolism where epilepsy is a feature, but apart from Alper's disease, status epilepticus is usually not the first symptom of the disorder.
12
With the exception of a few treatable epileptic encephalopathies, epilepsy associated with neurometabolic disorders is chronic and requires antiepileptic drugs for control. 12 More than half of our patients were on monotherapy; the majority of them experienced complete control using older generation antiepileptic drugs. In our study, epilepsy was well controlled in most patients with amino acid, organic acid, and urea cycle disorders ongoing with previous studies which reported epilepsy to be rare in cases with good metabolic control of the underlying disease. 4 Seizures were also well controlled in most of our patients (70%) with mitochondrial disorders compared to less than 50% control reported in previous studies. 17 Seizure types in our patients with mitochondrial disorders included tonic, myoclonic, and generalized tonic-clonic, while infantile spasms,, myoclonic jerks, astatic seizures, focal seizures, and juvenile myoclonic epilepsy were reported in previous studies. [28] [29] [30] Furthermore, 60% of patients with mitochondrial disorders reported in previous studies exhibited more than one seizure type. 31 In addition seizures were controlled in all our patients with metachromatic leukodystrophy; seizure types in our patients included myoclonic, focal, and generalized tonic-clonic. Both partial and generalized seizures were reported to occur in metachromatic leukodystrophy, with generalized seizures more common in patients with late infantile onset and partial seizures more common in those with juvenile onset of the metabolic disease. 19 In our patients with neuronal ceroid lipofusinosis, progressive myoclonic epilepsy was the main manifestation and none of our patients were responsive to anticonvulsants ongoing with results from previous studies. 4, 18 Nonresponsive patients in our study were resistant to both old and new antiepileptic medications. In such situations, tapering of the new and more expensive drug(s) and re-introduction of cheaper older generation drugs is encouraged to decrease the financial burden on the family, especially in countries with low incomes. However, some older generation drugs like valproate may worsen the clinical condition of certain metabolic disorders and should be avoided, especially in patients with mitochondriopathies, urea cycle deficiency, and nonketotic hyperglycinemia. 32 In about one third of our epileptic patients, the first EEG was normal. Abnormalities in EEG-positive patients in our study included both focal and generalized epileptic spikes, polyspikes, suppression bursts, and slow waves. The EEG findings in epilepsy associated with neurometabolic disorders are generally nonspecific; however, some EEG patterns are more suggestive of some disorders than others. For example, suppression burst are highly suggestive of nonketotic hyperglycinemia and paroxysmal responses during photic intermittent stimulation are highly suggestive of progressive myoclonic epilepsy. 12 Finally, the family history in our cohort included a high rate of consanguinity (77.1%), reflecting the autosomal recessive pattern of neurometabolic disorders. The presence of a family history of epilepsy in some patients (22.8%) most likely reflects the presence of the same neurometabolic disorder in other family members rather than a genetic predisposition to epilepsy.
Limitations of the study
This study has several limitations. It was retrospective; hospital based, and included a relatively small number of patients with a relatively short period of follow-up. Furthermore, other types of neurometabolic disorders could be associated with epilepsy but were not included in this study because no reliable diagnostic tests were available during the study period or because patients had severe presentation and died in hospital before presenting to the clinic.
Conclusion
This study has several important implications. By examining epilepsy in neurometabolic disorders as a collective group rather than disease by disease, this study emphasizes the fact that epilepsy is common in most neurometabolic disorders. Seizures in more than half of the patients were completely controlled, and around half of the patients required only monotherapy. Furthermore, around 75% of the patients responded to older generation antiepileptic drugs. Electroencephalographic findings are generally not specific to individual neurometabolic diseases or classes and can be normal initially, thus a high degree of suspicion and close monitoring is recommended.
